Last reviewed · How we verify
NCT04077372
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
NA trial testing Serious Illness Conversation Guide (SICG) in Gastrointestinal Cancer in 12 participants. Terminated before completion.
11 October 2020
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 12 |
| Start date | 16 September 2019 |
| Primary completion | 11 October 2020 |
| Estimated completion | 11 October 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Serious Illness Conversation Guide (SICG)
- Quality of Life (QOL) survey
Conditions studied
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Stanford University
Who can join
Eligibility, any sex, with Gastrointestinal Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04077372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
- NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
- NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04077372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 27 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04077372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing